MX2019004476A - Metodos para administrar un polipeptido neuroprotector al sistema nervioso central. - Google Patents
Metodos para administrar un polipeptido neuroprotector al sistema nervioso central.Info
- Publication number
- MX2019004476A MX2019004476A MX2019004476A MX2019004476A MX2019004476A MX 2019004476 A MX2019004476 A MX 2019004476A MX 2019004476 A MX2019004476 A MX 2019004476A MX 2019004476 A MX2019004476 A MX 2019004476A MX 2019004476 A MX2019004476 A MX 2019004476A
- Authority
- MX
- Mexico
- Prior art keywords
- neuroprotective polypeptide
- subject
- neuroprotective
- cns
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
- A61M5/14228—Pumping with an aspiration and an expulsion action with linear peristaltic action, i.e. comprising at least three pressurising members or a helical member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410748P | 2016-10-20 | 2016-10-20 | |
| PCT/US2017/057606 WO2018075901A1 (en) | 2016-10-20 | 2017-10-20 | Methods of delivering a neuroprotective polypeptide to the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004476A true MX2019004476A (es) | 2019-09-23 |
Family
ID=60382598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004476A MX2019004476A (es) | 2016-10-20 | 2017-10-20 | Metodos para administrar un polipeptido neuroprotector al sistema nervioso central. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273130B2 (enExample) |
| EP (2) | EP3528836A1 (enExample) |
| JP (2) | JP7626362B2 (enExample) |
| KR (2) | KR102687778B1 (enExample) |
| CN (1) | CN110191717A (enExample) |
| AU (1) | AU2017345724B2 (enExample) |
| BR (1) | BR112019008021A2 (enExample) |
| CA (1) | CA3040906A1 (enExample) |
| MX (1) | MX2019004476A (enExample) |
| SG (1) | SG11201903462UA (enExample) |
| WO (1) | WO2018075901A1 (enExample) |
| ZA (1) | ZA201902486B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102687778B1 (ko) | 2016-10-20 | 2024-07-23 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법 |
| CN114206374A (zh) * | 2019-07-29 | 2022-03-18 | 佩特通公司 | 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物 |
| MX2022001121A (es) | 2019-07-29 | 2022-02-16 | Peptron Inc | Composicion farmaceutica para el tratamiento de la disquinesia inducida por levodopa o para la supresion de la progresion de la misma. |
| EP4153214A4 (en) | 2020-05-22 | 2024-06-26 | Trustees of Boston University | Methods and compositions for treating a fibrotic disease |
| CN112014193B (zh) * | 2020-07-24 | 2021-06-15 | 武汉大学中南医院 | 一种新的fj染色方法和装置 |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| CN116392576A (zh) * | 2023-05-26 | 2023-07-07 | 南通大学 | 一种gip受体激动剂在制备治疗脊髓损伤修复靶点药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
| US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
| DE69720190T2 (de) | 1996-02-02 | 2003-12-11 | Alza Corp | Implantierbares system mit verzögerter freisetzung von leuprolid |
| ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
| MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| ES2293688T5 (es) | 1997-08-08 | 2011-05-04 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos análogos de la exendina. |
| CA2309356C (en) | 1997-11-14 | 2010-09-21 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| CA2315890C (en) | 1997-12-22 | 2009-08-11 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
| EP1041968B1 (en) | 1997-12-29 | 2004-03-03 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| ATE342051T1 (de) | 1997-12-30 | 2006-11-15 | Alza Corp | Verabreichungssystem für wirkstoffe mit einem membranstöpsel |
| DE69906132T2 (de) | 1998-12-31 | 2003-12-18 | Alza Corp., Mountain View | Osmotisches verabreichungsystem mit raumsparenden kolben |
| AU773354B2 (en) | 1999-12-21 | 2004-05-20 | Intarcia Therapeutics, Inc. | Valve for osmotic devices |
| US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| WO2004002565A1 (en) | 2002-06-26 | 2004-01-08 | Alza Corporation | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
| US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
| US7207982B2 (en) | 2003-03-31 | 2007-04-24 | Alza Corporation | Osmotic pump with means for dissipating internal pressure |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
| US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
| US8168222B2 (en) * | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
| EP2020990B1 (en) | 2006-05-30 | 2010-09-22 | Intarcia Therapeutics, Inc | Two-piece, internal-channel osmotic delivery system flow modulator |
| PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
| KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
| EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US9259432B1 (en) * | 2011-01-31 | 2016-02-16 | Parminder J. S. Vig | Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| JP6226510B2 (ja) | 2012-01-27 | 2017-11-08 | キヤノン株式会社 | 画像処理システム、処理方法及びプログラム |
| ITMI20130325A1 (it) | 2013-03-05 | 2014-09-06 | Telecom Italia Spa | Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente |
| JP2015192425A (ja) | 2014-03-28 | 2015-11-02 | 富士通株式会社 | デマンド収容変更順序決定方法、およびデマンド収容変更順序決定プログラム |
| EP3132790A4 (en) * | 2014-04-16 | 2017-11-22 | Shandong Luye Pharmaceutical Co., Ltd. | Exenatide-containing composition and preparation method therefor |
| KR102687778B1 (ko) | 2016-10-20 | 2024-07-23 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법 |
-
2017
- 2017-10-20 KR KR1020217022385A patent/KR102687778B1/ko active Active
- 2017-10-20 CA CA3040906A patent/CA3040906A1/en active Pending
- 2017-10-20 MX MX2019004476A patent/MX2019004476A/es unknown
- 2017-10-20 EP EP17800650.8A patent/EP3528836A1/en not_active Withdrawn
- 2017-10-20 US US16/342,685 patent/US11273130B2/en active Active
- 2017-10-20 WO PCT/US2017/057606 patent/WO2018075901A1/en not_active Ceased
- 2017-10-20 SG SG11201903462UA patent/SG11201903462UA/en unknown
- 2017-10-20 AU AU2017345724A patent/AU2017345724B2/en active Active
- 2017-10-20 JP JP2019521018A patent/JP7626362B2/ja active Active
- 2017-10-20 CN CN201780078697.6A patent/CN110191717A/zh active Pending
- 2017-10-20 KR KR1020197014421A patent/KR20190086460A/ko not_active Ceased
- 2017-10-20 EP EP25181393.7A patent/EP4635569A3/en active Pending
- 2017-10-20 BR BR112019008021-0A patent/BR112019008021A2/pt unknown
-
2019
- 2019-04-17 ZA ZA2019/02486A patent/ZA201902486B/en unknown
-
2021
- 2021-11-09 US US17/522,687 patent/US11771657B2/en active Active
-
2023
- 2023-02-06 JP JP2023016292A patent/JP2023065401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018075901A9 (en) | 2018-06-07 |
| US20200046645A1 (en) | 2020-02-13 |
| US20220265563A1 (en) | 2022-08-25 |
| ZA201902486B (en) | 2021-01-27 |
| CN110191717A (zh) | 2019-08-30 |
| RU2019115110A (ru) | 2020-11-24 |
| JP2020500163A (ja) | 2020-01-09 |
| US11771657B2 (en) | 2023-10-03 |
| WO2018075901A1 (en) | 2018-04-26 |
| CA3040906A1 (en) | 2018-04-26 |
| EP4635569A2 (en) | 2025-10-22 |
| US11273130B2 (en) | 2022-03-15 |
| AU2017345724A1 (en) | 2019-06-06 |
| EP4635569A3 (en) | 2025-12-31 |
| WO2018075901A8 (en) | 2019-05-23 |
| RU2019115110A3 (enExample) | 2021-03-02 |
| KR20190086460A (ko) | 2019-07-22 |
| KR20210092335A (ko) | 2021-07-23 |
| BR112019008021A2 (pt) | 2019-07-09 |
| JP7626362B2 (ja) | 2025-02-07 |
| JP2023065401A (ja) | 2023-05-12 |
| EP3528836A1 (en) | 2019-08-28 |
| AU2017345724B2 (en) | 2024-04-18 |
| SG11201903462UA (en) | 2019-05-30 |
| KR102687778B1 (ko) | 2024-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018075901A8 (en) | Methods of delivering a neuroprotective polypeptide to the central nervous system | |
| PH12020500286A1 (en) | Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases | |
| CO2020011068A2 (es) | Métodos y composiciones para la administración de proteínas terapéuticas | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EP4470595A3 (en) | Delivery of botulinum with microneedle arrays | |
| MX385287B (es) | Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. | |
| WO2016001924A3 (en) | Methods, devices and systems for pulmonary delivery of active agents | |
| HK1219661A1 (zh) | 用於治疗皮肤病的甲酰基肽受体2的激动剂的用途 | |
| NZ746784A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| UY30686A1 (es) | "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos" | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| PE20220337A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| PH12012500895A1 (en) | Method for treating heart failure with stresscopin-like peptides | |
| MX2019010982A (es) | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| RU2017126212A (ru) | Композиция | |
| EP4541367A3 (en) | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein | |
| HK1244231A1 (zh) | 使用hcg治疗慢性疼痛的方法和治疗 | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| AR104177A1 (es) | Sistema para la administración de fármacos en la glándula lagrimal | |
| GB2564026A (en) | Topical composition and delivery system and its use | |
| Dayama | Antithymocyte globulin/prednisolone |